doi: 10.1136/bmj.c869 Summary Keywords obesity, GLP-1, GLP-1 receptor analog, exenatide, pediatrics, glycemic control, GLP-1 receptor agonist, treatment Citation Stenlid R, Cerenius SY, Wen Q, Aydin BK, Manell H, Chowdhury A, Kristinsson H, Ciba I, Gjessing ES, Mrwald K, Gomahr J, Heu V, Weghuber D, Forslund A and Bergsten P (2023) Adolescents with obesity treated with exenatide maintain endogenous GLP-1, reduce DPP-4, and improve glycemic control
Persistent hunger returning after weeks of good appetite control is another signal that a higher dose might help
Other eye conditions may include: Papillitis swelling of your optic nerve Paracentral acute middle maculopathy a rare type of retinal damage Wet age-related macular degeneration new, leaky blood vessels under your retina In addition, fast changes in your blood sugar (especially when you start a GLP-1 drug) can temporarily affect the shape of your eye
This decline accelerates during caloric restriction, making the deficit state particularly catabolic
GLP-1 receptor agonists are authorised for the treatment of diabetes 1 or for weight management under certain conditions 2 or both 3
Brain fog starts to clear